SCM
PEARW

Saba Capital Management’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Saba Capital Management’s Portfolio PEARW Stock Details PEARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-211,664
Closed -$201K – 507
2021
Q1 		$201K Buy
+211,664
New +$206K 0.01% 370

Other funds holding PEARW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Saba Capital Management's PEARW Position: Q2 2021 in Review

Saba Capital Management sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2021, closing a stake of 211,664 shares — an estimated $201K sold.

Saba Capital Management first reported a position in PEARW in Q1 2021 and held it in 1 quarter. The position peaked at $201K in Q1 2021. 45 funds tracked by Wall St. Rank hold PEARW as of Q2 2021.

  • Saba Capital Management reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
  • Saba Capital Management sold 211,664 Pear Therapeutics, Inc. Warrant shares in Q2 2021, an estimated $201K.
  • Saba Capital Management first reported a position in Pear Therapeutics, Inc. Warrant in Q1 2021 and held it in 1 quarter.
  • Saba Capital Management's Pear Therapeutics, Inc. Warrant position peaked at $201K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2021.

Based on Saba Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.